Lipid Nanoparticle Composition for Extrahepatic Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge in delivering nucleic acids to cells efficiently and safely is hindered by their instability and low cellular permeability, with existing lipid nanoparticle (LNP) formulations primarily accumulating in the liver, limiting their clinical utility.
Innovation Solution
A novel lipid compound and lipid nanoparticle composition with high encapsulation efficiency and low toxicity, designed for extrahepatic delivery, incorporating specific lipid components and preparation methods to enhance targeted delivery of therapeutic agents like mRNA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional LNP formulations are used, then liver delivery efficiency is improved, but extrahepatic tissue delivery is limited
Solution Approach 1:
The patent modifies specific properties of the lipid nanoparticle components to achieve different delivery outcomes. By adjusting the ionizable lipid structure, PEG-lipid composition, and cholesterol content, the LNP formulation is optimized for either liver-specific delivery or extrahepatic tissue delivery, creating localized quality differences in the delivery system's behavior across different tissue types
Solution Approach 2:
The patent systematically varies key parameters of the LNP formulation including the molecular weight of PEG-lipid (2000 vs 4000), the molar ratios of lipid components, and the structural parameters of ionizable lipids. These parameter changes enable transition from liver-preferential accumulation to enhanced extrahepatic tissue delivery, resolving the contradiction between reliable liver delivery and versatile extrahepatic delivery
2Reliability
If nucleic acids are delivered directly to cells, then cellular permeability is poor, but stability is also low
Solution Approach 1:
The patent uses lipid nanoparticles as an intermediary carrier system. The LNP formulation includes ionizable lipids that can complex with nucleic acids, protecting them from degradation while providing a delivery vehicle that can interact with cell membranes. This intermediary system resolves the contradiction by providing both stability during circulation and facilitated cellular entry
Solution Approach 2:
The patent creates a composite delivery system combining multiple lipid types (ionizable lipids, PEG-lipids, cholesterol, phospholipids) with nucleic acids. This composite LNP formulation provides both the stability needed for nucleic acid protection and the cellular permeability required for effective delivery, as the different lipid components work synergistically
Data Source
AI summary
The present application disclosed a compound of formula (I) and a salt and a stereoisomer thereof, wherein each variable is as defined in the specification. The present application also disclosed a nanoparticle composition comprising the compound or a salt or a stereoisomer thereof, and the use of the nanoparticle composition for delivering active agents.